A Phase 2, 2-panel, Open-label, Randomized Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naïve Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

Janssen Sciences Ireland UC0 个研究点目标入组 40 人开始时间: 2015年3月30日最近更新: 2018年4月30日

适应症

试验速览

暂无简介。

•- Participants with chronic Hepatitis C Virus (HCV) genotype 1 infection between 18 to 70 years, inclusive, confirmed at screening
•- Participants must be treatment-naïve (that is, have not received prior treatment with any approved or investigational drug)
•- Participants with HCV ribonucleic acid (RNA) plasma levels greater than 10,000 international unit per milliliter (IU/ml) and lower than 6,000,000 international unit per milliliter (IU/ml) at screening
•- Participants with absence of cirrhosis confirmed by FibroTest/Fibrosure score less or equal to 0.75 and an aspartate aminotransferase to platelet ration index less or equal to 2 or a Fibroscan less or equal to 14.6 kilopascale (kPA), performed within 6 months prior or during the screening period
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 36
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 4

•- Participant has infection/co-infection with HCV of a genotype other than genotype 1, human immunodeficiency virus (HIV) type 1 or 2.
•- Participant has any evidence of liver disease of non-HCV etiology. This includes, but is not limited to acute hepatitis A, active hepatitis B, drug- or alcohol-related liver disease, autoimmune hepatitis, hemochromatosis, Wilson’s disease, alpha-1 antitrypsin deficiency, non-alcoholic steatohepatitis, primary biliary cirrhosis, or any other non-HC liver disease considered clinically significant by the investigator.
•- Participant with significant co-morbidities, conditions or clinical significant findings during screening assessments that in the opinion of the investigator could compromise the participants’ safety or could interfere with the Participant participating in and completing the study
•- Participant received an organ transplant (other than cornea or hair transplant or skin graft)
•- Participants have key protocol defined laboratory abnormalities

发起方